Unknown

Dataset Information

0

FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo.


ABSTRACT: Diagnosis in an advanced state is a major hallmark of ovarian cancer and recurrence after first line treatment is common. With upcoming novel therapies, tumor markers that support patient stratification are urgently needed to prevent ineffective therapy. Therefore, the transcription factor FOXM1 is a promising target in ovarian cancer as it is frequently overexpressed and associated with poor prognosis. In this study, fresh tissue specimens of 10 ovarian cancers were collected to investigate tissue cultures in their ability to predict individual treatment susceptibility and to identify the benefit of FOXM1 inhibition. FOXM1 inhibition was induced by thiostrepton (3 µM). Carboplatin (0.2, 2 and 20 µM) and olaparib (10 µM) were applied and tumor susceptibility was analyzed by tumor cell proliferation and apoptosis in immunofluorescence microscopy. Resistance mechanisms were investigated by determining the gene expression of FOXM1 and its targets BRCA1/2 and RAD51. Ovarian cancer tissue was successfully maintained for up to 14 days ex vivo, preserving morphological characteristics of the native specimen. Thiostrepton downregulated FOXM1 expression in tissue culture. Individual responses were observed after combined treatment with carboplatin or olaparib. Thus, we successfully implemented a complex tissue culture model to ovarian cancer and showed potential benefit of combined FOXM1 inhibition.

SUBMITTER: Bruckner L 

PROVIDER: S-EPMC7956612 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo.

Brückner Luzie L   Reinshagen Annika A   Hoang Ngoc Anh NA   Höhn Anne Kathrin AK   Lordick Florian F   Bechmann Ingo I   Aktas Bahriye B   Nel Ivonne I   Kallendrusch Sonja S  

Cancers 20210225 5


Diagnosis in an advanced state is a major hallmark of ovarian cancer and recurrence after first line treatment is common. With upcoming novel therapies, tumor markers that support patient stratification are urgently needed to prevent ineffective therapy. Therefore, the transcription factor FOXM1 is a promising target in ovarian cancer as it is frequently overexpressed and associated with poor prognosis. In this study, fresh tissue specimens of 10 ovarian cancers were collected to investigate tis  ...[more]

Similar Datasets

| S-EPMC8464600 | biostudies-literature
| S-EPMC6322000 | biostudies-literature
| S-EPMC2829112 | biostudies-other
| S-EPMC7539981 | biostudies-literature
| S-EPMC9328412 | biostudies-literature
| S-EPMC8233696 | biostudies-literature
| S-EPMC7059827 | biostudies-literature
| S-EPMC7673772 | biostudies-literature
| S-EPMC4926536 | biostudies-literature
| S-EPMC7183016 | biostudies-literature